A semiautomated method for quantification of F 18 florbetapir PET images

Journal of Nuclear Medicine

Volumn 56, Issue 11, 2015, Pages 1736-1741

  Joshi, Abhinay D ^a   Pontecorvo, Michael J ^a   Lu, Ming ^a   Skovronsky, Daniel M ^a   Mintun, Mark A ^a   Devous, Michael D ^a  

^a AVID RADIOPHARMACEUTICALS   (United States)

Author keywords

Alzheimer's; Florbetapir; Neuropathology; PET; Quantification

Indexed keywords

FLORBETAPIR F 18; AMYLOID PROTEIN; ANILINE DERIVATIVE; ETHYLENE GLYCOL DERIVATIVE; FLORBETAPIR; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; AUTOANALYSIS; AUTOPSY; CAUSE OF DEATH; CENTRUM SEMIOVALE; CEREBELLUM; COHORT ANALYSIS; CONTROLLED STUDY; GRAY MATTER; HUMAN; IN VIVO STUDY; INFORMED CONSENT; LIMIT OF QUANTITATION; MEAN CORTICAL STANDARDIZED UPTAKE VALUE RATIO; MEASUREMENT ACCURACY; PONS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SEMIAUTOMATED METHOD; SENILE PLAQUE; STANDARDIZATION; WHITE MATTER; AMYLOIDOSIS; AUTOMATION; BRAIN; FEMALE; IMAGE PROCESSING; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; PROCEDURES; REPRODUCIBILITY; SCINTISCANNING; STATISTICS AND NUMERICAL DATA; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOIDOGENIC PROTEINS; AMYLOIDOSIS; ANILINE COMPOUNDS; AUTOMATION; AUTOPSY; BRAIN; CEREBELLUM; ETHYLENE GLYCOLS; FEMALE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MALE; MIDDLE AGED; PONS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS;

EID: 84946599551     PISSN: 01615505     EISSN: 2159662X     Source Type: Journal    
DOI: 10.2967/jnumed.114.153494     Document Type: Article

References (23)

1. Klunk WE, Wang Y, Huang GF, Debnath ML, Holt DP, Mathis CA. Uncharged thioflavin-T derivatives bind to amyloid-beta protein with high affinity and readily enter the brain. Life Sci. 2001;69:1471-1484.
2. 18F) in patients with Alzheimer's disease and healthy controls: a multicenter phase 2 diagnostic study. Lancet Neurol. 2011;10:424-435.
3. 18F-BAY94-9172, a novel PET tracer: proof of mechanism. Lancet Neurol. 2008;7:129-135.
4. Clark CM, Schneider JA, Bedell BJ, et al. Use of florbetapir-PET for imaging b-amyloid pathology. JAMA. 2011;305:275-283.
5. Lopresti BJ, Klunk WE, Mathis CA, et al. Simplified quantification of Pittsburgh compound B amyloid imaging PET studies: a comparative analysis. J Nucl Med. 2005;46:1959-1972.
6. 11C] PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology. 2006;67: 446-452.
7. Braak H, Braak E. Neuro-pathological staging of Alzheimer-related changes. Acta Neuropathol (Berl). 1991;82:239-259.
8. Clark CM, Pontecorvo MJ, Skovronsky DM, et al. Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study. Lancet Neurol. 2012;11:669-678.
9. Evans AC, Marrett S, Bub D, et al. Anatomical mapping of functional activation in stereotactic coordinate space. Neuroimage. 1992;1:43-53.
10. 18F-AV-45 (florbetapir F 18). J Nucl Med. 2010;51:913-920.
11. Friston KJ, Ashburner JT, Kiebel SJ, Nichols TE, Penny WD, eds. Statistical Parametric Mapping: The Analysis of Functional Brain Images. London, U.K.: Academic Press; 2007:10-31.
12. Lancaster JL, Woldorff MG, Parsons LM, et al. Automated Talairach atlas labels for functional brain mapping. Hum Brain Mapp. 2000;10:120-131.
13. Lancaster JL, Rainey LH, Summerlin JL, et al. Automated labeling of the human brain: a preliminary report on the development and evaluation of a forward-transform method. Hum Brain Mapp. 1997;5:238-242.
14. Lancaster JL, Tordesillas-Gutierrez D, Martinez M, et al. Bias between MNI and Talairach coordinates analyzed using the ICBM-152 brain template. Hum Brain Mapp. 2007;28:1194-1205.
15. Smith SM. Fast robust automated brain extraction. Hum Brain Mapp. 2002;17: 143-155.
16. Rorden C, Brett M. Stereotaxic display of brain lesions. Behav Neurol. 2000;12:191-200.
17. Mirra SS, Heyman A, McKeel D, et al. The consortium to establish a registry for Alzheimer's disease (CERAD). Neurology. 1991;41:479-486.
18. Youden WJ. Index for rating diagnostic tests. Cancer. 1950;3:32-35.
19. Joshi AD, Pontecorvo MJ, Clark CM, et al. Performance characteristics of amyloid PET with florbetapir F 18 in patients with Alzheimer's disease and cognitively normal subjects. J Nucl Med. 2012;53:378-384.
20. Meyer JH, Gunn RN, Myers R, et al. Assessment of spatial normalization of PET ligand images using ligand-specific templates. Neuroimage. 1999;9:545-553.
21. Edison P, Carter SF, Rinne JO, et al. Comparison of MRI based and PET template based approaches in the quantitative analysis of amyloid imaging with PIB-PET. Neuroimage. 2013;70:423-433.
22. Landau SM, Breault C, Joshi AD, et al. Amyloid-β imaging with Pittsburgh compound B and florbetapir: comparing radiotracers and quantification methods. J Nucl Med. 2013;54:70-77.
23. 11C] PIB uptake in Alzheimers disease. Neurology. 2006;67:1575-1580.